Provided by Tiger Fintech (Singapore) Pte. Ltd.

Park Hotels & Resorts Inc.

11.28
+0.11000.98%
Volume:1.17M
Turnover:13.06M
Market Cap:2.25B
PE:18.51
High:11.29
Open:11.20
Low:11.08
Close:11.17
Loading ...

Design Therapeutics Announces Favorable Phase 1 Data for DT-168 Supporting Advancement into Phase 2 Biomarker Trial for Patients with Fuchs Endothelial Corneal Dystrophy

GlobeNewswire
·
01 May

BofA Securities Downgrades Park Hotels & Resorts to Underperform From Neutral

MT Newswires Live
·
30 Apr

Larimar Therapeutics Reports First Quarter 2025 Financial Results

GlobeNewswire
·
30 Apr

Affimed Shows Higher Exposure of AFM24 is Associated with Significantly Higher Response Rates and Progression-Free Survival in Refractory NSCLC Patients at AACR Annual Meeting

GlobeNewswire
·
29 Apr

Cingulate Announces Positive Top-Line Results from High-Dose (50mg) Fed/Fast Study of Lead Asset CTx-1301 for ADHD

GlobeNewswire
·
29 Apr

Easterly Government Properties (DEA) Lags Q1 FFO and Revenue Estimates

Zacks
·
29 Apr

Pasithea Therapeutics Announces Completion of Enrollment and Initial Dosing of Patients in Cohort 6 from its Phase 1 Trial of PAS-004 in Advanced Cancer Patients

GlobeNewswire
·
29 Apr

Seres Therapeutics Presents Data at the 2025 Digestive Disease Week Conference Highlighting the Potential for Live Biotherapeutics to Treat Inflammatory and Immune Diseases

GlobeNewswire
·
29 Apr

Chemomab Reports New Positive Clinical Data at EASL 2025 Supporting Nebokitug’s Impact in Primary Sclerosing Cholangitis and Related Diseases

GlobeNewswire
·
28 Apr

Bolt Biotherapeutics Presents Results from the Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025

GlobeNewswire
·
26 Apr

Zymeworks Presents New Data from Multiple Development Programs at 2025 AACR Annual Meeting

GlobeNewswire
·
26 Apr

Cogent Biosciences Presents Four Posters at the American Association for Cancer Research Annual Meeting 2025 and Announces Two New Leaders

GlobeNewswire
·
25 Apr